Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cloperastine→

Cloperastine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3703-76-2
Molecular formula
C20H24ClNO
Molecular weight
329.864 g/mol
Drug class
Non-opioid antitussivecentral cough suppressant with antihistaminic activity
Mechanism of action
Suppresses cough through central antitussive activity and has additional antihistaminic and anticholinergic properties. The precise molecular targets responsible for its clinical antitussive effect are not fully established.
Indications / reported uses
  • Symptomatic treatment of dry, non-productive cough in countries where cloperastine products are authorised; not intended to suppress productive cough where expectoration is required

Sources: NLM MeSH — Cloperastine · PubMed — Cloperastine antitussive pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cloperastine Environmental Risk Assessment (ERA) (the Cloperastine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.